The increase in medical device stocks increased in the afternoon. As of press release, Minimally Invasive Brain Science (02172) rose 6.46% to HK$9.4; Chunli Healthcare (01858) rose 4.61% to HK$9.31; Haohai Biotech (06826) rose 3.71% to HK$34.95; and Novi Health (06606) rose 2.35% to HK$18.28.
The Zhitong Finance App learned that medical device stocks increased in the afternoon. As of press release, Minimally Invasive Brain Science (02172) rose 6.46% to HK$9.4; Chunli Healthcare (01858) rose 4.61% to HK$9.31; Haohai Biotech (06826) rose 3.71% to HK$34.95; and Novi Health (06606) rose 2.35% to HK$18.28.
According to the news, Guojin Securities pointed out that based on reasons such as strong medical demand in overseas markets, sufficient profit space for products, manufacturing advantages and technological breakthroughs of domestic companies, and the resumption of foreign-funded medical device companies, it is optimistic about the future prospects of overseas expansion of domestic medical devices. It is recommended to focus on companies with advantages in product clinical innovation, manufacturing supply, and customer sticky channel layout.
According to the Tianfeng Securities Research Report, the Chinese medical device industry has experienced stages such as the entry of imported brands, learning and imitation by domestic companies, and industry catch-up, as China's manufacturing accumulation is weak, and all lines of R&D, production, and sales are strong. Future equipment going overseas mainly depends on channel construction and customer structure.